Literature DB >> 11969184

Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma.

Rosie Z Yu1, Brenda Baker, Alfred Chappell, Richard S Geary, Ellen Cheung, Arthur A Levin.   

Abstract

An ultrasensitive noncompetitive hybridization-ligation heterogeneous enzyme-linked immunosorbent assay was developed for the quantitation of antisense phosphorothioate oligodeoxynucleotides in plasma using a 96-well plate format. The principle of the assay is based on heterogeneous noncompetitive binding of the analyte to a template probe, followed by addition of signal probe via ligation and detection using a fluorescence microtiter plate reader. The result showed no significant interference noted from untreated human plasma. In addition, the method is selective for the specific sequence tested (ISIS 2302) and cross-reactivity toward the 3'-metabolites is minimal (< 0.22%). A linear range of 0.05 to 2 nM (r > 0.99) was obtained in human plasma for ISIS 2302. Intraday and interday accuracy for the method was found to be within 80-120% of actual value. Intraday and interday precision has a percentage coefficient of variation less than 20%. The lower limit of quantitation of the method was 0.05 nM (0.05 pmol/ml) with 100 microL plasma or an absolute amount of 5 fmol. In summary, the assay was demonstrated to be specific, accurate, precise, and sensitive for the quantitation of ISIS 2302 in human plasma and was applied to the analysis of plasma samples in pharmacokinetic studies. (c)2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11969184     DOI: 10.1006/abio.2002.5576

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  50 in total

1.  No effect on QT intervals of mipomersen, a 2'-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects.

Authors:  Rosie Z Yu; Rudy Gunawan; Zhaoyang Li; Robert S Mittleman; Asif Mahmood; John S Grundy; Walter Singleton; Richard Geary; Yanfeng Wang
Journal:  Eur J Clin Pharmacol       Date:  2015-12-09       Impact factor: 2.953

2.  A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices.

Authors:  Xiaohui Wei; Guowei Dai; Guido Marcucci; Zhongfa Liu; Dale Hoyt; William Blum; Kenneth K Chan
Journal:  Pharm Res       Date:  2006-05-25       Impact factor: 4.200

3.  Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.

Authors:  Ingrid E C Verhaart; Hans Heemskerk; Tatyana G Karnaoukh; Ingrid G M Kolfschoten; Anne Vroon; Gert-Jan B van Ommen; Judith C T van Deutekom; Annemieke Aartsma-Rus
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

4.  A novel ultrasensitive hybridization-based ELISA method for 2-methoxyphosphorothiolate microRNAs and its in vitro and in vivo application.

Authors:  Kenneth K Chan; Zhongfa Liu; Zhiliang Xie; Ming Chiu; Hongyan Wang; Ping Chen; Sarah Dunkerson; Michael Chiu; Shujun Liu; Georgia Triantafillou; Ramiro Garzon; Carlo M Croce; John C Byrd; Natarajan Muthusamy; Guido Marcucci
Journal:  AAPS J       Date:  2010-07-13       Impact factor: 4.009

5.  An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.

Authors:  Timothy M Miller; Alan Pestronk; William David; Jeffrey Rothstein; Ericka Simpson; Stanley H Appel; Patricia L Andres; Katy Mahoney; Peggy Allred; Katie Alexander; Lyle W Ostrow; David Schoenfeld; Eric A Macklin; Daniel A Norris; Georgios Manousakis; Matthew Crisp; Richard Smith; C Frank Bennett; Kathie M Bishop; Merit E Cudkowicz
Journal:  Lancet Neurol       Date:  2013-03-29       Impact factor: 44.182

6.  Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.

Authors:  Jeremy D Heidel; Zhongping Yu; Joanna Yi-Ching Liu; Shyam M Rele; Yongchao Liang; Ryan K Zeidan; Douglas J Kornbrust; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-22       Impact factor: 11.205

7.  Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe.

Authors:  Rosie Z Yu; Richard S Geary; Joann D Flaim; Gina C Riley; Diane L Tribble; André A vanVliet; Mark K Wedel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model.

Authors:  Hans Heemskerk; Christa de Winter; Petra van Kuik; Niki Heuvelmans; Patrizia Sabatelli; Paola Rimessi; Paola Braghetta; Gert-Jan B van Ommen; Sjef de Kimpe; Alessandra Ferlini; Annemieke Aartsma-Rus; Judith C T van Deutekom
Journal:  Mol Ther       Date:  2010-04-20       Impact factor: 11.454

9.  A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.

Authors:  S J H van Deventer; J A Tami; M K Wedel
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

10.  Tolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: a 'first in man' phase I investigation.

Authors:  Hermann Kain; David Goldblum; Bernard Geudelin; Eric Thorin; Christoph Beglinger
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.